Nitric Acid

Nitric Acid

SCHEMBL6033259

N=C(N)Nc1ccc2[nH]ncc2c1.O=[N+]([O-])O

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 6/20 0.57
ROCK1 Q13464 6/20 0.57
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
JAK2 O60674 2/20 0.52
POLB P06746 2/20 0.50
MAOB P27338 2/20 0.50
MAP4K4 O95819 2/20 0.50
RPS6KB1 P23443 2/20 0.50
CLK2 P49760 2/20 0.50
DYRK1A Q13627 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
PRKD3 O94806 1/20 0.50
PRKG1 Q13976 1/20 0.50
PRKD2 Q9BZL6 1/20 0.50
SGK2 Q9HBY8 1/20 0.50
STK17A Q9UEE5 1/20 0.50
MAPT P10636 1/20 0.50
NOS1 P29475 1/20 0.50
TMIGD3 P0DMS9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10310329 0.90 ROCK2 (0.63) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL5225654 0.79 ROCK2 (0.72) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL30933139 0.79 ROCK2 (0.72) ROCK2ROCK1NPC1RAB9AJAK2
Nitric Acid SCHEMBL7230493 0.78 NPC1 (0.50) NPC1RAB9AMAOBMAPT
Nitric Acid SCHEMBL7238568 0.76 CD40 (0.33) ROCK2ROCK1NPC1RAB9APOLB
SCHEMBL5823137 0.76 ROCK2 (0.63) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL1163706 0.74 ROCK2 (0.74) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL271133 0.73 RAB9A (0.70) ROCK2ROCK1NPC1RAB9AJAK2
SCHEMBL20611859 0.73 ROCK2 (0.64) ROCK2ROCK1NPC1RAB9AJAK2
Nitric Acid SCHEMBL6033263 0.73 MAPT (0.52) ROCK2ROCK1RAB9APOLBMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1187816-B1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES CELLTECH R&D LTD (GB) 2006-12-20 EP disclosed
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMTIED 2004-09-16 US disclosed
US-6579983-B1 Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase CELLTECH R&D LIMITED (GB) 2003-06-17 US disclosed
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2002-10-10 US disclosed
EP-1187816-A1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES Celltech R&D Limited (GB) 2002-03-20 EP disclosed
WO-2000078731-A1 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES CELLTECH R&D LIMITED (GB) 2000-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180914-A1 5-Cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR ROCK2 1996/4885ROCK1 714/4885NPC1 3120/4885
US-20020147339-A1 5-cyano-2-aminopyrimidine derivatives FLT1, FGFR1, KDR ROCK2 2053/4885ROCK1 730/4885NPC1 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.